Follow on Google News Industry News News By Place Country(s) Industry News
Follow on Google News | Cresset and Optibrium Announce Technology CollaborationTechnology exchange combines unique methods for design of novel, high quality compounds in drug discovery
By: Alto Marketing The collaboration will involve a two-way exchange of technologies: Achieving a combination of potency with appropriate ADME and safety properties is essential to the discovery of high quality drug candidates. Cresset’s molecular field technology provides unique insight into the biological activity, properties and interactions of molecules, which enables biologically meaningful comparisons that are not limited by two-dimensional structure. Optibrium’ Dr. Matthew Segall, CEO of Optibrium, said, “We are very happy to be working with the team at Cresset. This collaboration furthers our aim to deliver leading edge in silico technologies directly to the desktop of all drug discovery scientists through StarDrop’s user friendly, interactive interface. The new FieldAlign module in StarDrop will bring a powerful 3D view of compound interactions that will complement StarDrop’s existing 2D QSAR models.” Dr. Robert Scoffin, CEO of Cresset, added “This collaboration is an excellent opportunity for two companies to combine talents and technologies in order to offer a better product to our combined customers. This highlights the power of bringing together complementary technologies from leading-edge companies to better address problems in Drug Discovery.” The technology shared under this collaboration will form new components in upcoming releases of Optibrium's StarDrop and Cresset's desktop applications. Full details of these exciting new developments will be announced soon. For more information about StarDrop and Optibrium’s software solutions please visit www.optibrium.com, alternatively please call +44 (0) 1223 815 900 or email info@optibrium.com. For more information about Cresset’s software and service solutions please visit www.cresset- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|